Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (HK:2591)
:2591
Want to see HK:2591 full AI Analyst Report?
2591 Stock Chart & Stats
HK$30.42
--
Market closed
HK$30.42
--
Day’s Range― - ―
52-Week RangeHK$8.11 - HK$74.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)470.32K
Market Cap
HK$3.83B
Enterprise ValueHK$3.58B
Total Cash (Recent Filing)HK$1.21B
Total Debt (Recent Filing)HK$166.33M
Price to Earnings (P/E)―
Beta1.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding420,285,370
10 Day Avg. Volume352,882
30 Day Avg. Volume470,322
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)11.34
Price to Sales (P/S)93.25
P/FCF Ratio-37.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$28.10Price Target Upside-7.63% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue InflectionA clear 2025 revenue inflection shows commercialization traction and the start of durable top-line scale. If sustained, growing revenue can absorb fixed R&D and SG&A, reduce dependence on financing, and materially improve cash flow dynamics over a 2–6 month to multi-year horizon.
High Gross MarginAn ~81.5% gross margin implies the company’s products or services have strong unit economics. High gross profitability creates long-term leverage: as revenue scales, incremental sales convert to gross profit rapidly, supporting margin expansion and making sustained investment in commercialization more efficient.
Equity Cushion & Moderate LeverageMeaningful equity and low relative leverage provide a durable financial buffer for an R&D-heavy biotech. The capital base reduces immediate solvency risk and gives flexibility to fund clinical development or commercialization through near-term revenue scale or non-dilutive debt without imminent distress.
Bears Say
Persistent Cash BurnLarge negative operating and free cash flows indicate the business is still cash consuming despite revenue emergence. Continued burn requires recurring financing, raising dilution and refinancing risk, and limits the company's ability to self-fund growth until operating cash flow turns sustainably positive.
Very Large Operating LossesOperating losses far exceed current sales, showing the cost base is well ahead of commercialization scale. This structural imbalance means profitability is remote without significant expense discipline or faster revenue scaling, pressuring returns and strategic optionality over the medium term.
Rising Debt & Funding RiskMaterial debt increases in 2025, combined with ongoing negative returns, raise refinancing and interest burden risks. Higher leverage narrows financial flexibility, may force dilutive capital raises or costly debt, and elevates execution risk if revenue growth or cash generation disappoints.
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H News
2591 FAQ
What was Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price range in the past 12 months?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H lowest stock price was HK$8.11 and its highest was HK$74.00 in the past 12 months.
What is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s market cap?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s market cap is HK$3.83B.
When is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s earnings last quarter?
Currently, no data Available
Is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H overvalued?
According to Wall Street analysts Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price is currently Overvalued.
Does Guangzhou Innogen Pharmaceutical Group Co Ltd Class H pay dividends?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H does not currently pay dividends.
What is Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s EPS estimate?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guangzhou Innogen Pharmaceutical Group Co Ltd Class H have?
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H has 420,285,370 shares outstanding.
What happened to Guangzhou Innogen Pharmaceutical Group Co Ltd Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Guangzhou Innogen Pharmaceutical Group Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-39.43%
Trailing 12-Months
Asset Growth
75.89%
Trailing 12-Months
Company Description
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co Ltd operates as a China-based investment holding firm with a core mission to research, develop, and bring to market medicinal products. The company specializes in producing innovative, human-compatible, and extended-duration GLP-1 receptor agonists, specifically targeting the treatment of diabetes and other metabolic conditions.
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H (2591) Earnings & Revenues
2591 Stock 12 Month Forecast
Average Price Target
HK$28.10
▼(-7.63% Downside)
Technical Analysis
Alphamab Oncology
―
RemeGen Co. Ltd. Class H
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---